Granted Patent
B2
US 12,404,335 · App. 18/150,514 · Granted Sep 2, 2025
Compositions and methods for treatment of thyroid eye disease
Inventors:
Vahe Bedian (Waltham, MA); Peter Harwin (Dorado, PR); Tomas Kiselak (Dorado, PR); Angela She (Waltham, MA); Jonathan Violin (Waltham, MA); Yang Zhao (Waltham, MA)
Assignee:
Viridian Therapeutics, Inc.
C07K16/2863A61K9/0019A61P27/02A61K2039/505A61K2039/545C07K2317/24C07K2317/51C07K2317/515C07K2317/56C07K2317/565C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.
Claims (13)
1. An antibody comprising a light chain and a heavy chain, wherein:
the light chain comprises a light chain variable region comprising a LCDR1 of SEQ ID NO: 53, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 55; and
the heavy chain comprises a heavy chain variable region comprising a HCDR1 of SEQ ID NO: 56, a HCDR2 of SEQ ID NO: 57, and a HCDR3 of SEQ ID NO: 58, and an Fc region comprising an amino acid sequence of SEQ ID NO: 89.
2. A pharmaceutical composition comprising the antibody of claim 1 .
3. The antibody of claim 1 , wherein the antibody has an IC50 of less than or equal to 0.4 nM.
4. An antibody comprising a light chain and a heavy chain, wherein the light chain comprises an amino acid sequence of SEQ ID NO: 93 and the heavy chain comprises an amino acid sequence of SEQ ID NO: 94.
5. A pharmaceutical composition comprising the antibody of claim 4 .
6. The antibody of claim 4 , wherein the antibody has an IC50 of less than or equal to 0.4 nM.
7. An antibody comprising a light chain and a heavy chain, wherein
the light chain comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO: 13, and
the heavy chain comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 14, and an Fc region comprising an amino acid sequence of SEQ ID NO: 89.
8. A pharmaceutical composition comprising the antibody of claim 7 .
9. The antibody of claim 7 , wherein the antibody has an IC50 of less than or equal to 0.4 nM.
Assignments (2)
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Oct 20, 2025
From: VIRIDIAN THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 073121/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 6, 2023
From: BEDIAN, VAHE; HARWIN, PETER; KISELAK, TOMAS; SHE, ANGELA; VIOLIN, JONATHAN; ZHAO, YANG
To: VIRIDIAN THERAPEUTICS, INC.
Reel/Frame 062299/0858 →
Continuity (7)
Provisional Application
63261742
· Sep 28, 2021
Provisional Application
63260130
· Aug 10, 2021
Provisional Application
63201978
· May 21, 2021
Provisional Application
63091839
· Oct 14, 2020
References Cited (306)
US 4439196A
· Higuchi
· 1984
[cited by applicant]
US 4447224A
· DeCant, Jr. et al.
· 1984
[cited by applicant]
US 4447233A
· Mayfield
· 1984
[cited by applicant]
US 4487603A
· Harris
· 1984
[cited by applicant]
US 4596556A
· Morrow et al.
· 1986
[cited by applicant]
US 4790824A
· Morrow et al.
· 1988
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4941880A
· Burns
· 1990
[cited by applicant]
US 4949778A
· Saito et al.
· 1990
[cited by applicant]
US 5064413A
· McKinnon et al.
· 1991
[cited by applicant]
US 5260203A
· Ladner et al.
· 1993
[cited by applicant]
US 5312335A
· Mckinnon et al.
· 1994
[cited by applicant]
US 5383851A
· Mckinnon, Jr. et al.
· 1995
[cited by applicant]
US 5399163A
· Peterson et al.
· 1995
[cited by applicant]
US 5475096A
· Gold et al.
· 1995
[cited by applicant]
US 5831012A
· Nilsson et al.
· 1998
[cited by applicant]
US 6004746A
· Brent et al.
· 1999
[cited by applicant]
US 6005079A
· Casterman et al.
· 1999
[cited by applicant]
US 6096002A
· Landau
· 2000
[cited by applicant]
US 6620135B1
· Weston et al.
· 2003
[cited by applicant]
US 6794144B1
· Saksela et al.
· 2004
[cited by applicant]
US 6818418B1
· Lipovsek et al.
· 2004
[cited by applicant]
US 6994982B1
· Watt et al.
· 2006
[cited by applicant]
US 7083784B2
· Dall'Acqua et al.
· 2006
[cited by applicant]
US 7166697B1
· Galanis et al.
· 2007
[cited by applicant]
US 7186524B2
· Kolmar et al.
· 2007
[cited by applicant]
US 7250297B1
· Beste et al.
· 2007
[cited by applicant]
US 7417130B2
· Stumpp et al.
· 2008
[cited by applicant]
US 7572897B2
· Graus et al.
· 2009
[cited by applicant]
US 7670600B2
· Dall'Acqua et al.
· 2010
[cited by applicant]
US 7803907B2
· Stemmer et al.
· 2010
[cited by applicant]
US 7838629B2
· Fiedler et al.
· 2010
[cited by applicant]
US 7998681B2
· Smith et al.
· 2011
[cited by applicant]
US 8137933B2
· Saha
· 2012
[cited by applicant]
US 8153121B2
· Smith et al.
· 2012
[cited by applicant]
US 8394925B2
· Chamberlain et al.
· 2013
[cited by applicant]
US 8951790B2
· Saha
· 2015
[cited by applicant]
US 9045536B2
· Merchant et al.
· 2015
[cited by applicant]
US 9982036B2
· Bossenmaier et al.
· 2018
[cited by applicant]
US 20040023334A1
· Prior
· 2004
[cited by applicant]
US 20040132094A1
· Etzerodt et al.
· 2004
[cited by applicant]
US 20040146938A1
· Nguyen et al.
· 2004
[cited by applicant]
US 20040157209A1
· Yilmaz et al.
· 2004
[cited by applicant]
US 20040202651A1
· Cohen et al.
· 2004
[cited by applicant]
US 20040209243A1
· Nixon et al.
· 2004
[cited by applicant]
US 20060286103A1
· Kolhe et al.
· 2006
[cited by applicant]
US 20070041972A1
· Rother et al.
· 2007
[cited by applicant]
US 20080014203A1
· Hansen et al.
· 2008
[cited by applicant]
US 20080112888A1
· Wang
· 2008
[cited by applicant]
US 20080226635A1
· Koll et al.
· 2008
[cited by applicant]
US 20090275126A1
· Graus et al.
· 2009
[cited by applicant]
US 20100104645A1
· Ali et al.
· 2010
[cited by applicant]
US 20100119446A1
· Grabulovski et al.
· 2010
[cited by applicant]
US 20100143340A1
· Kolhe et al.
· 2010
[cited by applicant]
US 20100260668A1
· Ghayur et al.
· 2010
[cited by applicant]
US 20110014117A1
· Wang et al.
· 2011
[cited by applicant]
US 20110014207A1
· Gualberto et al.
· 2011
[cited by applicant]
US 20110044980A1
· Ghayur et al.
· 2011
[cited by applicant]
US 20110229933A1
· Krishnan et al.
· 2011
[cited by applicant]
US 20110263827A1
· Ghayur et al.
· 2011
[cited by applicant]
US 20120014957A1
· Ghayur et al.
· 2012
[cited by applicant]
US 20120076778A1
· Koll et al.
· 2012
[cited by applicant]
US 20120100166A1
· Roschke et al.
· 2012
[cited by applicant]
US 20120201746A1
· Liu et al.
· 2012
[cited by applicant]
US 20120237507A1
· Bossenmaier et al.
· 2012
[cited by applicant]
US 20120263722A1
· Ghayur et al.
· 2012
[cited by applicant]
US 20130004416A1
· Wu et al.
· 2013
[cited by applicant]
US 20130195871A1
· Ghayur et al.
· 2013
[cited by applicant]
US 20130259868A1
· Roschke et al.
· 2013
[cited by applicant]
US 20140050729A1
· Yao
· 2014
[cited by applicant]
US 20140079665A1
· Goetsch et al.
· 2014
[cited by applicant]
US 20150017168A1
· Ghayur et al.
· 2015
[cited by applicant]
US 20150056191A1
· Sathyanarayanan et al.
· 2015
[cited by applicant]
US 20150168424A1
· Wang
· 2015
[cited by applicant]
US 20160060299A1
· Luesch
· 2016
[cited by applicant]
US 20160096894A1
· Cohen et al.
· 2016
[cited by applicant]
US 20160151487A1
· Hartmann et al.
· 2016
[cited by applicant]
US 20170218091A1
· Ambrosi
· 2017
[cited by applicant]
US 20180243432A1
· Poma et al.
· 2018
[cited by applicant]
US 20210253719A1
· Sherman et al.
· 2021
[cited by applicant]
US 20210284741A1
· Madden et al.
· 2021
[cited by applicant]
US 20220088231A1
· Burak
· 2022
[cited by examiner]
US 20220235137A1
· Bedian et al.
· 2022
[cited by applicant]
US 20220267450A1
· Bedian et al.
· 2022
[cited by applicant]
US 20220267451A1
· Bedian et al.
· 2022
[cited by applicant]
US 20220275096A1
· Bedian et al.
· 2022
[cited by applicant]
US 20230002495A1
· Bedian et al.
· 2023
[cited by applicant]
US 20230084477A1
· O'Shaughnessy et al.
· 2023
[cited by applicant]
US 20240043546A1
· Bedian
· 2024
[cited by examiner]
US 20240343814A1
· Bedian et al.
· 2024
[cited by applicant]
US 20240352133A1
· Bedian
· 2024
[cited by examiner]
US 20240360227A1
· Bedian et al.
· 2024
[cited by applicant]
US 20240368282A1
· Schlegel et al.
· 2024
[cited by applicant]
US 20250099583A1
· Huyghe et al.
· 2025
[cited by applicant]
CN 101229371A
· 2008
[cited by applicant]
CN 101292036A
· 2008
[cited by applicant]
CN 113402602A
· 2021
[cited by applicant]
EP 0404097A2
· 1990
[cited by applicant]
EP 1399483B1
· 2010
[cited by applicant]
EP 1689782B1
· 2010
[cited by applicant]
EP 2235059A1
· 2010
[cited by applicant]
EP 1959014B1
· 2011
[cited by applicant]
EP 2230254B1
· 2013
[cited by applicant]
EP 2681239B1
· 2015
[cited by applicant]
EP 2032989B2
· 2015
[cited by applicant]
EP 2681240B1
· 2017
[cited by applicant]
EP 2194067B1
· 2017
[cited by applicant]
EP 2863947B1
· 2018
[cited by applicant]
EP 2714733B1
· 2019
[cited by applicant]
EP 1469879B1
· 2019
[cited by applicant]
EP 2970433B1
· 2019
[cited by applicant]
EP 2814500B1
· 2020
[cited by applicant]
EP 2322550B1
· 2020
[cited by applicant]
EP 3458101B1
· 2020
[cited by applicant]
KR 20210094669
· 2021
[cited by examiner]
TW 202228775A
· 2022
[cited by applicant]
WO 1988001649A1
· 1988
[cited by applicant]
WO 1993011161A1
· 1993
[cited by applicant]
WO 1994004678
· 1994
[cited by applicant]
WO 1994004678A1
· 1994
[cited by applicant]
WO 1994025591
· 1994
[cited by applicant]
WO 1994025591A1
· 1994
[cited by applicant]
WO 03100008A2
· 2003
[cited by applicant]
WO 03106621A2
· 2003
[cited by applicant]
WO 2006060419A2
· 2006
[cited by applicant]
WO 2007062037A2
· 2007
[cited by applicant]
WO 2008005469A2
· 2008
[cited by applicant]
WO 2008076278A2
· 2008
[cited by applicant]
WO 2008079849A2
· 2008
[cited by applicant]
WO 2011028811A2
· 2011
[cited by applicant]
WO 2011161119A1
· 2011
[cited by applicant]
WO 2014177459A2
· 2014
[cited by applicant]
WO 2016064716A1
· 2016
[cited by applicant]
WO 2017011773A2
· 2017
[cited by applicant]
WO 2019084026A1
· 2019
[cited by applicant]
WO 2019084030A1
· 2019
[cited by applicant]
WO 2019173352A1
· 2019
[cited by applicant]
WO 2019183523A1
· 2019
[cited by applicant]
WO 2020006486A1
· 2020
[cited by applicant]
WO 2020132091A2
· 2020
[cited by applicant]
WO 2021041773
· 2021
[cited by examiner]
WO 2021041773A1
· 2021
[cited by applicant]
WO 2021243014A1
· 2021
[cited by applicant]
WO 2022081799A1
· 2022
[cited by applicant]
WO 2022081804A1
· 2022
[cited by applicant]
WO 2022187510A1
· 2022
[cited by applicant]
WO 202301917A1
· 2023
[cited by applicant]
WO 2023019171A1
· 2023
[cited by applicant]
WO 2023122714A2
· 2023
[cited by applicant]
WO 2023133485A2
· 2023
[cited by applicant]
WO 2023133486A2
· 2023
[cited by applicant]
WO 2023133561A1
· 2023
[cited by applicant]
WO 2025014774A1
· 2025
[cited by applicant]
Guelberto et al (Oncogene 28(34):3008-3021 (Aug. 27, 2009)).
[cited by examiner]
Final Office Action dated Sep. 19, 2023 for U.S. Appl. No. 17/450,872, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability received in PCT Appl. No. PCT/US2022/074764 mailed Feb. 13, 2024.
[cited by applicant]
International Search Report and Written Opinion for Appl. No. PCT/US2022/082214 mailed Jul. 3, 2023.
[cited by applicant]
International Search Report and Written Opinion for Appl. No. PCT/US2023/060206 mailed Jun. 21, 2023.
[cited by applicant]
International Search Report and Written Opinion for Appl. No. PCT/US2023/060207 mailed Jun. 30, 2023.
[cited by applicant]
Non-Final Office Action dated Nov. 4, 2022 for U.S. Appl. No. 17/822,978, 18 pages.
[cited by applicant]
Non-Final Office Action dated Nov. 7, 2022 for U.S. Appl. No. 17/501,362, 17 pages.
[cited by applicant]
Notice of Allowance dated Nov. 30, 2022 for U.S. Appl. No. 17/822,978, 12 pages.
[cited by applicant]
Allen et al., “A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease”. Ophthalmology. (2021) S0161-6420(21)00167-6. doi: 10.1016/j.ophtha.2021.03.006. Epub ahead of print. PMID: 33823982.
[cited by applicant]
Baert, et al. “Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease” New Engl. J. Med. (2003) 348:601-608.
[cited by applicant]
Beniaminovitz et al. “Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor With a Monoclonal Anibody”, New Engl. J. Med. (2000) vol. 342: No. 9, pp. 613-619.
[cited by applicant]
Chen et al., “Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Ingibits TSH and IGF-1 Action in Fibrocytes”, J Clin Endocrinol Metab (2014) 99(9):E1635-E1640.
[cited by applicant]
Chiou et al., “Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases.” American Journal of Ophthalmology Case Reports (2021): 101075.
[cited by applicant]
Chothia, et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulis”, J Mol. Biol. (1987) 196:901-917.
[cited by applicant]
Chothia, et al., “Conformations of Immunoglobulin hypervariable regions”, Nature (1989) 342:877-883.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT01868997—Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease, 9 pages.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT03298867—Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (Optic), 11 pages.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT03461211—Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X), 8 pages.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT03498417—Anti-insulin-like Growth Factor-1 Receptor (IGF-1 R) Antibodies in Graves' Disease and Graves' Orbitopathy (IGF1 RAbsGO), 7 pages.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT04040894—Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP), 7 pages.
[cited by applicant]
ClinicalTrials.gov Identifier: NCT04583735—A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease, 9 pages.
[cited by applicant]
Diniz et al., “Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population”. Ophthalmic Plast Reconstr Surg. (2021) doi: 10.1097/IOP.0000000000001959. Epub ahead of print. PMI…
[cited by applicant]
Dolgin, “IGF-1R drugs travel from cancer cradle to Graves'. Nat Biotechnol”. (2020) 38(4):385-388. doi: 10.1038/s41587-020-0481-8. PMID: 32265558.
[cited by applicant]
Dosiou et al, “Thyroid Eye Disease: Navigating The New Treatment Landscape.” Journal of the Endocrine Society (2021).
[cited by applicant]
Douglas et al., “Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis”. J Immunol. (2007) 178(5):3281-…
[cited by applicant]
Douglas et al., “B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis”. J Immunol. (2008) 181(8):5768-74. doi: 10.4049/jimmunol.181.8.5768. PMID: 188327…
[cited by applicant]
Douglas et al., “Teprotumumab for the Treatment of Active Thyroid Eye Disease”. N Engl J Med. (2020) 382(4):341-352. doi: 10.1056/NEJMoa1910434. PMID: 31971679.
[cited by applicant]
Douglas, “Teprotumumab, an insulin-lik growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis”, Spring Nature (2019) 33:13-190.
[cited by applicant]
Edmunds et al., “Investigation of candidate biomarkers in Graves' disease and thyroid-associated ophthalmopathy”. Diss. University of Birmingham, (2016).
[cited by applicant]
Ghosh et al., “Natalizumab for Active Chrohn's Disease”, New Engl. J. Med. (2003) 348:24-32.
[cited by applicant]
Herold, et al., “ANTI-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus”, New Engl. J. Med. (2002) vol. 346, No. 22, pp. 1692-1698.
[cited by applicant]
Hoa et al., “Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17”. PLoS One. (2012) 7(4):e34173. doi: 10.1371/journal.pone.0034173. Epub Apr. 10, 2012. PMID: 22506015…
[cited by applicant]
Holliger et al., ““Diabodies”: Small bivalent and bispecific antibody fragments”, Proc. Natl. Acad. Sci. USA (1993) vol. 90 pp. 6444-6448.
[cited by applicant]
Holliger et al., “Engineered Antibody Fragments and the Rise of Single Domains”, Nat. Biotechnol. (2005) vol. 23, No. 9, pp. 1126-1136.
[cited by applicant]
International Preliminary Report on Patentability received in PCT Appl. No. PCT/US2021/054907 mailed Apr. 13, 2023.
[cited by applicant]
International Preliminary Report on Patentability received in PCT Appl. No. PCT/US2021/054914 mailed Apr. 13, 2023.
[cited by applicant]
International Search Report and Written Opinion for International PCT Application No. PCT/US2022/074764 dated Nov. 4, 2022.
[cited by applicant]
International Search Report and Written Opinion received in Appl. No. PCT/US2021/054907 mailled Feb. 23, 2022.
[cited by applicant]
International Search Report and Written Opinion received in PCT Appl. No. PCT/US2021/054914 mailed Feb. 23, 2022 .
[cited by applicant]
Jain et al., “Teprotumumab reduces extraocular muscle and orbital fat vol. in thyroid eye disease”. Br J Ophthalmol. (2020) bjophthalmol-2020-317806. doi: 10.1136/bjophthalmol-2020-317806. Epub ahead of print. PMID: 331…
[cited by applicant]
Janssen et al., “Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Cells”. (2021) 10(2):383. doi: 10.3390/cells10020383. PMID: 33673340; PMCID: PMC7917650.
[cited by applicant]
Kabat, et al., “Unusual Distributions of Amino Acids in Complementarity-determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combininb Sit…
[cited by applicant]
Kahaly et al., “Management of Graves Thyroidal and Extrathyroidal Disease: An Update”. J Clin Endocrinol Metab. (2020) 105(12):3704-20. doi: 10.1210/clinem/dgaa646. PMID: 32929476; PMCID: PMC7543578.
[cited by applicant]
Keenan et al., “A First-in-Human Phase 1 Randomized, Single-Ascending Dose Study of Lonigutamab, an Anti-IGF-1R Monoclonal Antibody, in Healthy Volunteers”, Presented at the 49th North American Neuro-Ophthalmology Socie…
[cited by applicant]
Krieger et al., “Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins”. J Clin Endocrinol Metab. (2015( (3):1071-7. doi: 10.1210/jc.2014-3566. Epu…
[cited by applicant]
Krieger et al., “Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?” Int J Mol Sci. (2020) 21(18):6561. doi: 10.3390/ijms21186561. PMID: 32911689; PMCID: PMC7555308.
[cited by applicant]
Krieger et al., “Thyrotropin/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis”. J Clin Endocrinol Metab. (2016) 101(6):2340-7. doi: 10.1210/jc.2016-1315. Epub Apr. 4, 2016. PMID: 27043163; PMCID: PMC4891…
[cited by applicant]
Kumar et al., “A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody”. J Clin Endocrinol Metab. (2012) 97(5):168…
[cited by applicant]
Lanzolla et al., “Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study”. J Endocrinol Invest. (2020) 3(12):1759-1768. doi: 10.1007/s40…
[cited by applicant]
Lathe, et al., “Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data Theoretical and Practical Considerations”, J. Molec. Biol. (1985) 183:1 12.
[cited by applicant]
Lipsky et al., “Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis”, New Engl. J. Med. (2000) 343:1594-1602).
[cited by applicant]
Liu et al. “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells”, Proc. Natl. Acad. Sci., USA (1987) vol. 84, pp. 3439-3443.
[cited by applicant]
Liu et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.”, J Immunology (1987) 139:3521-3526.
[cited by applicant]
Liu, et al., “Randomised, double blind, placebo controlled study of interferon ß-1a in a relapsing-remitting multiple sclerosis analysed by area under disability/time curves” J. Neurol. Neurosurg. Psych. (1999) 67:451-4…
[cited by applicant]
Marinò et al., “Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy”. J Endocrinol Invest. (2019) 42(4):471-480. doi: 10.1007/s40618-018-0943-8. Epub Au…
[cited by applicant]
Markham, “Teprotumumab: First Approval. Drugs”. (2020) 80(5):509-512. doi: 10.1007/s40265-020-01287-y. PMID: 32157641.
[cited by applicant]
Marks et al., “By-passign Immunization Human Antibodies from V-gene Libraries Displayed on Phage”, J. Mol. Biol. (1991) 222:pp. 581-597.
[cited by applicant]
Milgrom et al., “Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody,” New Engl. J. Med. (1999) 341:1966-1973.
[cited by applicant]
Morgan et al., “Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes”. Thyroid. (2016) (12):1794-1803. doi: 10.1089/thy.2…
[cited by applicant]
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc. Natl. Acad. Sci. USA (1984) vol. 81: pp. 6851-6855.
[cited by applicant]
Mueller et al,, “Humanized Porcine VCAM-Specific Monoclonal Antibodies With Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells”, Mol Immunol (1997) vol. 34, No. 6. pp. 441-452.
[cited by applicant]
Muyldermans et al., “Recognition of antigens by single-domain fragments: the superfluous luxury of paired domains”, Trends Biochem. Sci. (2001) vol. 26, No. 4, pp. 230-235.
[cited by applicant]
Neumann et al., “Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease”. Eur Thyroid J. (2020) (Suppl 1):59-65. doi: 10.1159/000511538. Epub Nov. 2, 2020. PMID: 33511086; PMCID: PMC7802449.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/724,639 dated Aug. 19, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/818,798 dated Jun. 27, 2023.
[cited by applicant]
Non-Final Office Action from U.S. Appl. No. 17/450,872 dated Jan. 26, 2023.
[cited by applicant]
Osher et al., “Therapeutic Targeting of the IGF Axis. Cells”. (2019) 8(8):895. doi: 10.3390/cells8080895. PMID: 31416218; PMCID: PMC6721736.
[cited by applicant]
Ozzello et al., “Early experience with teprotumumab for chronic thyroid eye disease”. Am J Ophthalmol Case Rep. (2020) 19:100744. doi: 10.1016/j.ajoc.2020.100744. PMID: 32462101; PMCID: PMC7243051.
[cited by applicant]
Place et al., “Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro”. Br J Pharmacol. (2017) 174(4):328-340. doi: 10.1111/bph.13…
[cited by applicant]
Pluckthun (1994) The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315.
[cited by applicant]
Portielji et al., “IL-12: A Promising Adjuvant for Cancer Vaccination,” Cancer Immunol. Immunother. (2003) 52:133-144.
[cited by applicant]
Presta, “Molecular mechanisms in allergy and clinical immunology, Selection, design, and engineering of therapeutic antibodies”, J. Allergy Clin. Immunol. (2005) 116:731-736.
[cited by applicant]
Pritchard et al., “Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway”. J Immunol. (200…
[cited by applicant]
Reichmann et al., “Single domain antibodies: comparison of camel VH and camelised human VH domains”, J. Immunol. Methods (1999) pp. 231:25.
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy”. Nature (1988). 332 (6162): 332-323.
[cited by applicant]
Safo et al., “A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease”. Am J Ophthalmol Case Rep. (2021) 22:101069. doi: 10.1016/j.ajoc.2021.101069. PMID: 33817409; PMCID: PMC8008157.
[cited by applicant]
Salvi el al., “Medical Treatment of Graves' Orbitophathy”, Horm Metab Res (2015) 47:779-788.
[cited by applicant]
Salvi, “Immunotherapy for Graves' ophthalmopathy”, curr Opin Endocrinol Diabetes Obes. (2014) 21 (5):409-14.
[cited by applicant]
Slamon et al., “Use of Chemotherapy Plus a Monoclonal Antibodty Against HER2 for Metastatic Breast Cancer That Overexpresses HER2”, N Engl. J. Med. (2001) vol. 344, No. 11, pp. 783-792.
[cited by applicant]
Slentz et al., “Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy”. Expert Opin Investig Drugs. (2020) (7):645-649. doi: 10.1080/13543784.2020.1772752. Epub Jun. 10, 2020. PMID:…
[cited by applicant]
Smith et al. “Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.”, J Clin Endocrinol Metab. (2004…
[cited by applicant]
Smith et al., “Teprotumumab for Thyroid-Associated Ophthalmopathy”. N Engl J Med. (2017) 376(18): 1748-1761. doi: 10.1056/NEJMoa1614949. PMID: 28467880; PMCID: PMC5718164.
[cited by applicant]
Smith, “Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy”. Front Endocrinol (Lausanne). (2020) 11:610337. doi: 10.3389/fendo.2020.610337. PMID: 33391187; PMCID: PMC7774640.
[cited by applicant]
Smith, T. J., “Teprotumumab for Thyroid-Associated Ophthalmopathy”, N Engl J Med (2017) 376:18, pp. 1748-1761.
[cited by applicant]
Storz et al., “Intellectual property protection”, MAbs. (2011) 3(3): 15530, pp. 310-317.
[cited by applicant]
Taylor et al., “New insights into the pathogenesis and nonsurgical management of Graves orbitopathy”. Nat Rev Endocrinol. (2020) 16(2):104-116. doi: 10.1038/s41574-019-0305-4. Epub Dec. 30, 2019. PMID: 31889140.
[cited by applicant]
Tsui et al., “Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease”. J Immunol. (2008) 181(6):4397-405. doi: 10…
[cited by applicant]
Tsurushita et al., “Humanization of a chicken anti-IL-12 monoclonal antibody” Journal of Immunological Methods (2004) 295, pp. 9-19.
[cited by applicant]
Ugradar et al., “Improvement of asymmetric thyroid eye disease with teprotumumab”, Br J Ophthalmol. (2021): bjophthalmol-2020-318314. doi: 10.1136/bjophthalmol-2020-318314. Epub ahead of print. PMID: 33579690.
[cited by applicant]
Ugradar et al., “Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye”, Lond (2020) doi: 10.1038/s41433-020-01297-w. Epub ahead of print. PMID: 33221815.
[cited by applicant]
Ugrader et al., “A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface,” J. Neuroophthalmol. (Mar. 2022) 42(1), pp. 26-34. (Abstract Only).
[cited by applicant]
Ugrader et al., “Teprotumumab for the Treatment of Chronic Thyroid Eye Disease,” Eye (Aug. 2022) 36(8), pp. 1553-1559.
[cited by applicant]
Weightman el al., “Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity”. (1993) 16(4):251-7. doi: 10.3109/08916939309014643. PMID: 7517705.
[cited by applicant]
Xin Y, Xu F, Gao Y, Bhatt N, Chamberlain J, Sile S, Hammel S, Holt RJ, Ramanathan S. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Th…
[cited by applicant]
Yang, et al., “A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Groth Factor Antibody, for Metastatic Renal Cancer”, New Engl. J. Med. (2003) 349:427-434.
[cited by applicant]
Yu R. Thyroid function suppression after initiation of teprotumumab treatment. Endocrine. Mar. 15, 2021. doi: 10.1007/s12020-021-02676-3. Epub ahead of print. PMID: 33721204.
[cited by applicant]
NANOS2023_Keenan Poster # 293 “A First-in-Human Phase 1 Randomized, Single-Ascending Dose Study of Lonigutamab, an Anti-IGF-1R Monoclonal Antibody, in Healthy Volunteers”, 1 page.
[cited by applicant]
International Search Report for PCT/US2024/036800 dated Jan. 16, 2025 (7 pages).
[cited by applicant]
International Search Report for PCT/US2024/036803 dated Dec. 12, 2024 (8 pages).
[cited by applicant]
International Search Report for PCT/US2024/045630 dated Jan. 27, 2025 (5 pages).
[cited by applicant]
International Search Report for PCT/US2024/060579 dated Apr. 3, 2025 (6 pages).
[cited by applicant]
International Search Report for PCT/US2025/010700 dated Apr. 24, 2025 (5 pages).
[cited by applicant]
Partial Search Report for PCT/US2024/036800 dated Oct. 21, 2024 (13 pages).
[cited by applicant]
Partial Search Report for PCT/US2024/036803 dated Oct. 21, 2024 (30 pages).
[cited by applicant]
Partial Search Report for PCT/US2025/010706 dated May 13, 2025 (11 pages).
[cited by applicant]
Partial Search Report for PCT/US2025/010718 dated May 12, 2025 (34 pages).
[cited by applicant]
“A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)”, ClinicalTrials.gov, U.S. National Library of Medicine, May 23, 2024, NCT06384547 (8 pages).
[cited by applicant]
“A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) (Thrive)”, ClinicalTrials.gov, U.S. National Library of Medicine, Dec. 3, 2021, N…
[cited by applicant]
“An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)”, ClinicalTrials.gov, U.S. National Library of Medicine, Nov. 14, 2023, NCT06021054 (9 pages).
[cited by applicant]
“International Nonproprietary Names for Pharmaceutical Substances (INN)”, Who Drug Information, vol. 22, No. 4, Jan. 1, 2008 URL: https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl…
[cited by applicant]
Cui, Xuejiao , et al., “A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves; orbitopathy”, Frontiers in Immunology, vol. 19, Jan. 19, 2023 (12 pages).
[cited by applicant]
Dall'Acqua, William F., et al., “Properties of human IgG1 s engineered for enhanced binding to the neonatal Fe receptor (FcRn)”, Journal of Biological Chemistry, vol. 281, No. 33, Jun. 21, 2006 (pp. 23514-23524).
[cited by applicant]
Foster, Kelly , et al., “6461 VRDN-003, A Full Antagonist Antibody To The IGF-1 Receptor For Thyroid Eye Disease (TED): Safety And Pharmacokinetic Results Of Subcutaneous Administration In Healthy Volunteers”, Abstract,…
[cited by applicant]
Foster, Kelly , et al., “Thyroid FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED”,…
[cited by applicant]
Kamboj , et al., “Emerging Therapies in the Medical Management of Thyroid Eye Disease”, Frontiers in Ophthalmology, vol. 3, 1295902, Dec. 12, 2023, DOI:10.3389/fopht.2023.1295902 (5 pages).
[cited by applicant]
Ludgate, Marian , “Fibrosis in dysthyroid eye disease”, Eye, vol. 34, No. 2, Dec. 16, 2019 (pp. 279-284).
[cited by applicant]
Patel, Amy , et al., “A New Era in the Treatment of Thyroid Eye Disease”, American Journal of Ophthalmology, vol. 208, Aug. 1, 2019 (pp. 281-288).
[cited by applicant]
Robbie, Gabriel J., et al., “A Novel Investigational Fe-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults”, Antimicrobial Agents and Chemotherapy, vol. 57, No. 12, Sep.…
[cited by applicant]
Cited By (2)